# 2DR Versus 3DR in a Prospective Randomized Controlled Switch Trial

> **NCT04553081** · PHASE4 · RECRUITING · sponsor: **University Hospital, Ghent** · enrollment: 134 (estimated)

## Conditions studied

- HIV-1-infection

## Interventions

- **DRUG:** Dual versus triple therapy in treatment of HIV-1 infection.

## Key facts

- **NCT ID:** NCT04553081
- **Lead sponsor:** University Hospital, Ghent
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2020-05-26
- **Primary completion:** 2026-06-30
- **Final completion:** 2027-04-30
- **Target enrollment:** 134 (ESTIMATED)
- **Last updated:** 2024-02-28

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04553081

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04553081, "2DR Versus 3DR in a Prospective Randomized Controlled Switch Trial". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT04553081. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*